Pallas Health vs IVIM Health: Clinician choice and ratings

Pallas Health vs IVIM Health: Pallas centers on a clinician choice between FDA-approved brand-name GLP-1s and US-compounded semaglutide or tirzepatide, with compounded plans starting at $139 first month; IVIM Health emphasizes a clinician-guided GLP-1 ID protocol, dual 4.9-star ratings, and a low entry price with a $75 start and a GIFT75 free-month code. Early verdict: choose Pallas if you want access to both brand and compounded options from a single intake and an all-in plan price; choose IVIM if a low starting cost, third-party ratings, and a proprietary optimization protocol matter more to you.

Pallas Health vs IVIM Health: How they differ

This comparison focuses on the most distinctive supported differences: medication options and clinician selection, pricing and billing cadence, satisfaction signals and protocol claims, and program features such as membership and care inclusion. Each point uses only the facts provided by the two providers.

1. Medication offerings and clinician selection

Pallas offers both FDA-approved brand-name drugs including Wegovy, Ozempic, Zepbound and Mounjaro and clinician-personalized compounded semaglutide or tirzepatide prepared in the USA when a brand medication is not the right fit. IVIM provides compounded semaglutide and tirzepatide only, prescribed after consultation with an Ivím provider. Pallas explicitly states a US-licensed clinician reviews your history and personalizes whether brand or compounded medication is chosen. IVIM prescribes compounded drugs only after clinical evaluation and uses a proprietary GLP-1 ID protocol for titration and optimization.

2. Pricing structure and payment details

Pallas documents compounded semaglutide as $139 first month then $597 every 12 weeks, a $199 per month average, and compounded tirzepatide as $179 first month then $897 every 12 weeks, a $299 per month average. Pallas notes brand-name options are cash pay with listed monthly prices and that the platform is cash-pay only. IVIM lists a $75 starting price and compound tirzepatide at $133 per month plus a $74.99 monthly program fee in captured landing-page text, and advertises a GIFT75 free-month-membership code. IVIM also includes a no-obligation free consultation valued at $75 for new patients. Both providers state compounded medications are not FDA-approved and operate on a direct-pay model rather than billing insurance.

3. Satisfaction signals and protocol claims

IVIM highlights a 4.9-star rating on both Google and Trustpilot and a proprietary protocol claiming up to 40 percent faster weight loss versus a referenced trial, with the company noting that claim is proprietary and not an independent head-to-head study. Pallas highlights clinician personalization, multiple FDA-approved branded options, and LegitScript Healthcare Merchant Certification with published clinical disclosures. IVIM cites published retrospective studies and internal outcomes but notes these are not randomized head-to-head trials and that results may vary.

4. Program features, membership, and care inclusion

Pallas promotes a one all-in plan price where provider care, check-ins and messaging are included with no membership fee, asynchronous care in most states, and free expedited shipping. Pallas also notes care-team hours and that a video visit is required in seven states plus Washington D.C. IVIM promotes a clinically structured program with weekly dose adjustments and program fees in some plans, plus the GIFT75 free-month-membership code and a free consultation for new patients.

Side-by-side snapshot

Pallas Health vs IVIM Health: Practical takeaways

Both platforms prescribe compounded GLP-1 medicines that are not FDA-approved and use clinician review. Pallas is distinct for offering brand-name options alongside compounded preparations from one intake and packaging provider care into an all-in plan price. IVIM is distinct for a low-cost entry, a free consultation offer, a free-month code, and strong third-party ratings along with a proprietary GLP-1 ID protocol and published retrospective studies.

Choose based on these facts

Choose Pallas Health if you want a clinician to choose between brand-name GLP-1 pens and a US-compounded alternative within the same intake, prefer an all-in plan price that includes provider care and messaging, and value documented eligibility review by a US-licensed clinician.

Choose IVIM Health if you want the lowest listed entry price, value dual 4.9-star external ratings, want a no-obligation free consultation and the option to use the GIFT75 free-month-membership code, or prefer a proprietary GLP-1 ID protocol and published retrospective outcome studies. Both providers note compounded medications are not FDA-approved and both operate on a cash-pay model. Consider clinician eligibility, state availability, and the regulatory notes each provider supplies before deciding.